|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net income (loss) | |||||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | |||||
| Provision for credit losses | |||||
| Impairment of goodwill | |||||
| Loss on impairment of intangible assets | |||||
| Provision for (benefit from) credit losses | |||||
| Loss on sale of assets | |||||
| Loss on impairment | |||||
| Right-of-use amortization | |||||
| Amortization of debt issuance costs | |||||
| Deferred income taxes, net | |||||
| Unrealized net gain on warrants | |||||
| Change in fair value of equity securities | |||||
| Loss on disposal of inventory | |||||
| Net gain on exercise and cancellation of warrants | |||||
| Foreign currency transaction (gain) loss | |||||
| Gain on sale of business | |||||
| Change in fair value of acquisition-related contingent consideration | |||||
| Loss (gain) on revaluation of finance receivables | |||||
| Foreign currency transaction gains | |||||
| Loss on marketable investments | |||||
| Loan discount amortization and fee accretion | |||||
| Interest paid-in-kind | |||||
| Stock-based compensation | |||||
| Depreciation and amortization expense | |||||
| Changes in operating assets and liabilities: | |||||
| Interest and accounts receivable | |||||
| Interest, accounts receivable and other receivables | |||||
| Derivative assets and liabilities, net | |||||
| Collateral on foreign currency forward contract | |||||
| Other assets, net | |||||
| Accounts payable, accrued expenses, and other non-current liabilities | |||||
| Deferred income | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities: | |||||
| Proceeds from sale of investment and finance receivables | |||||
| Cash received from settlement of warrants and equity securities | |||||
| Sale of finance receivables | |||||
| Proceeds from sale of property and equipment | |||||
| Settlement of foreign currency forward contract | |||||
| Proceeds from sale of assets and liabilities held for sale | |||||
| Sale of marketable investments | |||||
| Investment in finance receivables | |||||
| Repayment of finance receivables | |||||
| Corporate debt securities principal payments | |||||
| Purchases of property and equipment | |||||
| Net cash provided by (used in) investing activities | |||||
| Cash flows from financing activities: | |||||
| Net settlement for employee taxes on stock options | |||||
| Net payments on from credit facility | |||||
| Cash dividends | |||||
| Payments on financing costs | |||||
| Proceeds from senior unsecured notes | |||||
| Repurchases of common stock, including fees and expenses | |||||
| Net cash used in financing activities | |||||
| Net increase in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of period | |||||
| Cash and cash equivalents at end of period | |||||
| Warrants received in connection with finance receivables | |||||
| Supplemental non-cash investing and financing activities: | |||||
| Derecognition of right-of-use assets and operating lease liabilities upon termination of lease | |||||
| Cash paid for interest | |||||
| Fair value of common stock received upon exercise of warrant | |||||
| Fair value of warrants received with finance receivables | |||||
Loading...